Wen‐Zhao Zhong
Xihua University(CN)Shandong University(CN)Sun Yat-sen University(CN)Zunyi Medical University(CN)Sichuan University(CN)Augusta University(US)Hull College(GB)Cancer Institute (WIA)(IN)ShanghaiTech University(CN)Agricultural Genomics Institute at Shenzhen(CN)West China Hospital of Sichuan University(CN)Nanfang Hospital(CN)Chinese Academy of Agricultural Sciences(CN)Shantou Central Hospital(CN)Advanced Materials and Devices (United States)(US)Guangdong Academy of Medical Sciences(CN)Ministry of Agriculture and Rural Affairs(CN)Guangdong Provincial People's Hospital(CN)Heilongjiang University(CN)Southern Medical University(CN)South China University of Technology(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma(2016)984 cited
- → Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study(2017)524 cited
- → EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer(2017)436 cited
- → Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer(2024)336 cited
- → Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy(2018)329 cited
- → Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial